GLP-1s are rewriting the cost conversation
As glucagon-like peptide-1 (GLP-1) access expands, employers may need to weigh coverage trade-offs, cost pressures and other ways to support weight and metabolic health.
- Employers are feeling the cost pressure. As GLP-1 demand continues to grow, employers are carefully weighing employee interest and potential health benefits against rising pharmacy costs and plan affordability.
- Coverage decisions are becoming more complex. Many employers who previously covered GLP-1s are reconsidering that strategy or evaluating who qualifies, how appropriate use is managed and how effectiveness is measured over time. Plus, as access to these drugs expands, even employers who choose not to cover GLP-1s are seeing implications on their bottom line due to increased utilization from side effects by those who elect to pay out-of-pocket for these medications.
- GLP-1s may not be the only solution. While they may offer meaningful support for clinically appropriate candidates, long-term value may depend on further evidence and guidance around adherence combined with broader lifestyle supports and care management.
GLP-1 medications have moved quickly from a clinical breakthrough to a benefits pressure point. More employees are asking about them, more physicians are prescribing them, and more employers are seeing the impact in their cost trends. At the same time, government initiatives and market efforts to expand access to GLP-1s are creating new questions about what role employer-sponsored coverage should play.
The financial pressure is becoming harder to ignore for employers that offer or are considering coverage of GLP-1s. A recent report found that GLP-1 medications represented 20.3% of overall prescription spending among the report’s analyzed employer population, up from 17.5% the previous year.1
That leaves employers with a more complicated decision than simply whether to cover the medications. They may need to weigh immediate pharmacy costs against potential long-term health value, employee interest against plan affordability, and how alternate access channels may influence utilization.
Why GLP-1 demand is changing the benefits conversation
Originally developed to help manage type 2 diabetes, GLP-1 medications have expanded into weight management as clinical evidence, consumer awareness and prescribing have grown.
11%
of U.S. adults take GLP-1 medications for weight loss2
That shift has changed how employers may need to think about their benefits. What was once viewed primarily as a treatment for diabetes is now part of a broader discussion about obesity, metabolic health, pharmacy trend, employee expectations and benefit affordability. As of 2026, 11% of U.S. adults take GLP-1 medications for weight loss, while 15% report having used them at some point for weight loss.2
And the price tag remains significant: GLP-1s cost plan sponsors almost $7,400 a year in 2025.1 For self-funded employers in particular, higher utilization can show up directly in pharmacy costs, making the coverage decision harder to separate from overall affordability goals.
That is where the trade-off becomes clearer. GLP-1s may offer meaningful support for people who are clinically appropriate candidates, but coverage can also create immediate and significant cost pressure for the plan.
The challenge is that costs and outcomes may not show up on the same balance sheet. Employers may see the pharmacy cost right away, while any potential medical savings tied to improved weight, diabetes or cardiometabolic health may take longer to appear. At the same time, it may be difficult for an employer to determine whether an employee is taking a GLP-1 and whether the medication is contributing to increased utilization in other areas of the plan. For example, common side effects may lead to ER visits.
While GLP-1s can offer meaningful clinical benefits related to weight loss for some members, many employers are still evaluating how to manage their direct and indirect impact on overall medical and pharmacy costs.
“We have not yet seen total cost of care decrease for GLP-1s that are being used for weight loss, so I think employer groups are starting to question whether or not they should continue to cover them.”
What to weigh before making a coverage decision
Before deciding whether to cover GLP-1s, employers may need to clarify what they are trying to solve. That may include deciding whether to cover the drugs, how coverage should be managed and how to support employees who want to lose weight even if their plan does not cover GLP-1s for that use.
Employers may want to answer these questions, for instance:
Who qualifies?
How will adherence be supported?
How will success be measured?
What trade-offs may be needed if utilization keeps growing?
How will the employer explain the strategy and available support options to employees?
Coverage may be easier to evaluate when employers have clear criteria for who qualifies, how clinical need is confirmed and what utilization management tools may be needed. For example, some plans are using strategies, such as prior authorization, eligibility requirements or participation in weight management programs to help align coverage with clinical need.
≈54%
of adults taking GLP-1 therapy discontinued within 1 year3
Even when employees meet those criteria, it may not be enough to support long-term value. A 2025 study found that around 54% of adults who were taking GLP-1 therapy discontinued the medication within 1 year.3 The study also found that adverse events and cost were among the most common documented reasons for stopping treatment.3 For employers, that reinforces why coverage decisions may need to account for adherence, affordability and ongoing support — not just initial access.
Since GLP-1 utilization has quadrupled since 2024 and is expected to continue rising, employers may also want to consider how they’ll balance the increased costs against other benefits priorities, especially as the access landscape continues to shift.2
Two-thirds of surveyed employers currently cover GLP-1s for weight management, but many are imposing utilization controls to manage appropriate use. These controls include verifying clinical eligibility with biometric data, requiring participation in weight management programs, restricting prescribing to certain providers and excluding select medications. Despite these strategies, cost pressures are prompting some employers to reconsider coverage. Only 72% of those covering GLP-1s for weight management say they are likely to continue that coverage in 2027.4
Federal and state policy discussions, manufacturer programs, cash-pay options and other market activity may create additional ways for some employees to access GLP-1s outside of their employer-sponsored benefit. That may not eliminate the need for an employer strategy, but it could help relieve some pressure on employers to be the only path to access.
How employers can support weight health beyond coverage
Not covering GLP-1s for weight loss does not mean stepping back from employee health. It may mean taking a broader view of weight management — one that balances affordability, sustainability and the support employees may need over time.
As Craig Kurtzweil, chief data and analytics officer for UnitedHealthcare Employer & Individual, has noted, “GLP-1s shouldn’t be looked at as a single-point solution.”
That support may start with helping employees understand their health, benefits and care options. Because weight is often linked to physical, behavioral and social factors, support may need to go beyond one medication or program. Employers can still offer meaningful support through lifestyle management programs, behavioral health resources, clinical resources, condition management programs, wellness tools and education around nutrition, physical activity, stress, sleep and chronic conditions.
Clear communication can also be an important tool. Employees may have questions about why GLP-1s are or are not covered, what alternatives are available and where to go for support. A clear strategy can help set expectations, reduce confusion and point employees to resources that may help them take the next step.
For employers, the goal is not to solve weight health through coverage alone. GLP-1s may remain part of the conversation, but a sustainable strategy also includes helping employees access the right care, understand their options and engage with support that can help improve health over time.
Share
